Reported Earlier, Roivant Announced That Results From The Phase 2 Phocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-ild) Will Be Presented At The European Respiratory Society International Congress 2026 On Tuesday, September 8, 2026